Get Started

IPHA

NASD Innate Pharma SA Sponsored ADR
Nov 5, 2026 · 12:52 PM ET DELAYED Market Open

$1.41 ↓ -0.02 (-1.05%) Trading Down from the previous close of $1.43, $0.02 below the day’s high of $1.43

YTD change
-19.43%
vs 20-day SMA
-4.64%
vs 200-day SMA
-17.48%

Price ranges

Previous day
$1.38 $1.43
open $1.40 close $1.43
+$0.03 (+1.79%)
Today
$1.40 $1.43
open $1.44 now $1.41
-$0.03 (-2.08%)
Past week
$1.32 $1.52
from $1.52 now $1.41
-$0.11 (-7.24%)
Past month
$1.32 $1.68
from $1.52 now $1.41
-$0.11 (-7.24%)
This year
$1.17 $2.71
from $1.75 now $1.41
-$0.34 (-19.43%)

Price & Performance

+0.03 (+1.79%) / 6M

$1.22$1.69$2.16$2.63May 5Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 88.2% away from all-time highs of $11.95
  • IPHA is down 19% since the beginning of the year
  • IPHA is down 23% over the past 12 months
  • IPHA is down 7% over the past 1 month
  • 0% of all IPHA investors are betting against IPHA

IPHA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -21.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.241206
Earnings momentum -60.6% Quarterly EPS growth
Quarterly change -60.6%

Valuation

P/E ratio N/A
Enterprise value $144.3M
Beta 1.13

Balance sheet & scale

IncomeN/A
Revenue$5.0M
Cash$12.5M
Debt$23.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $157.0M

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $930.67 -4.39%
IQV IQVIA Holdings Inc $263.79 +0.46%
CRL Charles River Laboratories International, Inc. $326.29 -7.27%
ICLR ICON Plc $203.11 -0.32%
IT Gartner, Inc. $207.19 +1.45%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.